Hospital costs in the US for pulmonary mycobacterial diseases

Mehdi Mirsaeidi, Mary Beth Allen, Golnaz Ebrahimi, Dean Schraufnagel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. Methods: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. Results: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P= 0.001). However, no such increase was found for national hospital costs of pulmonary TB. Conclusions: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalInternational Journal of Mycobacteriology
Volume4
Issue number3
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Nontuberculous Mycobacteria
Hospital Costs
Lung Diseases
Pulmonary Tuberculosis
Costs and Cost Analysis
Lung
Chronic Disease Hospitals
United States Dept. of Health and Human Services
Mycobacterium tuberculosis
Health Care Costs
Linear Models
Tuberculosis
Hospitalization
Guidelines

Keywords

  • Healthcare costs
  • Nontuberculous mycobacteria
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Hospital costs in the US for pulmonary mycobacterial diseases. / Mirsaeidi, Mehdi; Allen, Mary Beth; Ebrahimi, Golnaz; Schraufnagel, Dean.

In: International Journal of Mycobacteriology, Vol. 4, No. 3, 01.09.2015, p. 217-221.

Research output: Contribution to journalArticle

Mirsaeidi, Mehdi ; Allen, Mary Beth ; Ebrahimi, Golnaz ; Schraufnagel, Dean. / Hospital costs in the US for pulmonary mycobacterial diseases. In: International Journal of Mycobacteriology. 2015 ; Vol. 4, No. 3. pp. 217-221.
@article{c7c0d0fd9c1d475eb60f962988a5f4fa,
title = "Hospital costs in the US for pulmonary mycobacterial diseases",
abstract = "Background: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. Methods: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. Results: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P= 0.001). However, no such increase was found for national hospital costs of pulmonary TB. Conclusions: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.",
keywords = "Healthcare costs, Nontuberculous mycobacteria, Tuberculosis",
author = "Mehdi Mirsaeidi and Allen, {Mary Beth} and Golnaz Ebrahimi and Dean Schraufnagel",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.ijmyco.2015.05.003",
language = "English (US)",
volume = "4",
pages = "217--221",
journal = "International Journal of Mycobacteriology",
issn = "2212-5531",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Hospital costs in the US for pulmonary mycobacterial diseases

AU - Mirsaeidi, Mehdi

AU - Allen, Mary Beth

AU - Ebrahimi, Golnaz

AU - Schraufnagel, Dean

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. Methods: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. Results: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P= 0.001). However, no such increase was found for national hospital costs of pulmonary TB. Conclusions: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.

AB - Background: Pulmonary mycobacterial diseases describe both tuberculosis (TB) and nontuberculous mycobacteria (NTM). Few data are available measuring the cost burden of mycobacterial diseases at the national level. The purpose of this study is to evaluate the cost burden and measure emerging trends in hospitalization of pulmonary TB and NTM cases in the United States from 2001 through 2012. Methods: This study is a retrospective, community-based cost analysis of hospitalized patients with a principal diagnosis of pulmonary mycobacterial diseases from 2001 through 2012. Data for pulmonary TB and NTM were retrieved from the Healthcare Cost and Utilization Project (HCUP), US Department of Health and Human Services. The statistical significance of observed trends of NTM and TB national hospital costs was calculated using Poisson log-linear regression. Results: 20,049 hospital discharges were reported for pulmonary NTM and 69,257 for pulmonary TB in the US from 2001 through 2012. The total associated cost of these discharges was $903,767,292 for pulmonary NTM and $2,078,113,317 for pulmonary TB. During the study period, the national hospital costs of pulmonary NTM increased at a statistically significant rate in the US over each year (P= 0.001). However, no such increase was found for national hospital costs of pulmonary TB. Conclusions: The national hospital cost of NTM management is increasing. These results emphasize the importance of continued research in pulmonary NTM in order to improve current guidelines in prevention and treatment strategies.

KW - Healthcare costs

KW - Nontuberculous mycobacteria

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84938747118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938747118&partnerID=8YFLogxK

U2 - 10.1016/j.ijmyco.2015.05.003

DO - 10.1016/j.ijmyco.2015.05.003

M3 - Article

AN - SCOPUS:84938747118

VL - 4

SP - 217

EP - 221

JO - International Journal of Mycobacteriology

JF - International Journal of Mycobacteriology

SN - 2212-5531

IS - 3

ER -